| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CA19-9 |
| Uniprot No | P20849 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-921aa |
| 氨基酸序列 | MKTCWKIPVFFFVCSFLEPWASAAVKRRPRFPVNSNSNGGNELCPKIRIGQDDLPGFDLISQFQVDKAASRRAIQRVVGSATLQVAYKLGNNVDFRIPTRNLYPSGLPEEYSFLTTFRMTGSTLKKNWNIWQIQDSSGKEQVGIKINGQTQSVVFSYKGLDGSLQTAAFSNLSSLFDSQWHKIMIGVERSSATLFVDCNRIESLPIKPRGPIDIDGFAVLGKLADNPQVSVPFELQWMLIHCDPLRPRRETCHELPARITPSQTTDERGPPGEQGPPGPPGPPGVPGIDGIDGDRGPKGPPGPPGPAGEPGKPGAPGKPGTPGADGLTGPDGSPGSIGSKGQKGEPGVPGSRGFPGRGIPGPPGPPGTAGLPGELGRVGPVGDPGRRGPPGPPGPPGPRGTIGFHDGDPLCPNACPPGRSGYPGLPGMRGHKGAKGEIGEPGRQGHKGEEGDQGELGEVGAQGPPGAQGLRGITGIVGDKGEKGARGLDGEPGPQGLPGAPGDQGQRGPPGEAGPKGDRGAEGARGIPGLPGPKGDTGLPGVDGRDGIPGMPGTKGEPGKPGPPGDAGLQGLPGVPGIPGAKGVAGEKGSTGAPGKPGQMGNSGKPGQQGPPGEVGPRGPQGLPGSRGELGPVGSPGLPGKLGSLGSPGLPGLPGPPGLPGMKGDRGVVGEPGPKGEQGASGEEGEAGERGELGDIGLPGPKGSAGNPGEPGLRGPEGSRGLPGVEGPRGPPGPRGVQGEQGATGLPGVQGPPGRAPTDQHIKQVCMRVIQEHFAEMAASLKRPDSGATGLPGRPGPPGPPGPPGENGFPGQMGIRGLPGIKGPPGALGLRGPKGDLGEKGERGPPGRGPNGLPGAIGLPGDPGPASYGRNGRDGERGPPGVAGIPGVPGPPGPPGLPGFCEPASCTMQAGQRAFNKGPDP |
| 预测分子量 | 91,8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CA19-9重组蛋白的模拟参考文献(内容为示例，非真实文献)：
---
1. **标题**: *"Expression and Purification of Recombinant CA19-9 Antigen in Escherichia coli for Immunoassay Development"*
**作者**: Smith J., et al.
**摘要**: 研究报道了利用大肠杆菌表达系统高效生产重组CA19-9蛋白的方法，通过His标签纯化获得高纯度抗原，验证其在ELISA检测中与传统血清标志物的一致性，为诊断试剂开发提供基础。
2. **标题**: *"Structural Characterization of Recombinant CA19-9 Glycoform and Its Clinical Validation in Pancreatic Cancer"*
**作者**: Wang L., et al.
**摘要**: 通过哺乳动物细胞表达系统获得糖基化修饰的重组CA19-9蛋白，分析其糖链结构并证明其与胰腺癌患者血清样本的结合特异性，提示其在肿瘤分期中的潜在应用价值。
3. **标题**: *"Development of a CA19-9-Specific Monoclonal Antibody Using Recombinant Protein as Immunogen"*
**作者**: Tanaka K., et al.
**摘要**: 利用重组CA19-9蛋白免疫小鼠，筛选出高亲和力单克隆抗体，验证其与天然CA19-9的交叉反应性，为新型免疫检测技术的开发提供关键试剂。
---
*注：以上为示例性内容，实际文献需通过PubMed、Web of Science等数据库检索。建议使用关键词"CA19-9 recombinant protein"+"expression/diagnosis/structure"查找最新研究。*
CA19-9 recombinant protein is a synthetically produced glycoprotein widely used in biomedical research and clinical diagnostics. The antigen CA19-9. originally identified in 1979. is a sialylated Lewis blood group antigen (sialyl Lewis-a) expressed on specific glycoproteins and glycolipids. It is best known as a tumor-associated biomarker, elevated in pancreatic ductal adenocarcinoma (PDAC), colorectal cancer, and other gastrointestinal malignancies. However, CA19-9 is not cancer-specific and may also increase in benign conditions like pancreatitis or cholestasis, limiting its diagnostic specificity.
Recombinant CA19-9 is engineered using mammalian expression systems (e.g., CHO or HEK293 cells) to mimic the natural glycosylation patterns critical for antibody recognition. This involves cloning the gene encoding the protein backbone—often MUC1 or other mucin-family proteins—followed by post-translational modification to add sialyl Lewis-a epitopes. The recombinant protein serves as a standardized tool for developing immunoassays, calibrating diagnostic tests, and validating CA19-9 detection antibodies. It also facilitates studies on tumor biology, metastasis, and cell adhesion mechanisms mediated by carbohydrate-antigen interactions.
Despite its utility, challenges persist in ensuring batch-to-batch consistency due to glycosylation complexity. Researchers increasingly employ glycoengineering approaches to improve reproducibility. Additionally, recombinant CA19-9 aids in exploring therapeutic strategies, such as antibody-drug conjugates or vaccines targeting CA19-9-expressing cancers. Its role extends to monitoring treatment response and recurrence in cancer patients, though clinical interpretation requires caution due to the biomarker’s non-specificity. Ongoing efforts focus on enhancing its diagnostic accuracy through multi-marker panels and advanced detection technologies.
×
